Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Inolimomab

Alternative Names: inolimomab, Leukotac
Clinical Status: Inactive
Latest Update: 2023-06-20
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: IL2 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ElsaLys Biotech
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Graft vs Host Disease|Allogeneic Stem Cell Transplant

Phase 2: Allogeneic Stem Cell Transplant|Graft vs Host Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
ATUC-LKT

N/A

Available

Graft vs Host Disease

None

2021-09-19

Primary Endpoints|Treatments
2006-005019-81

P2

Completed

Allogeneic Stem Cell Transplant|Graft vs Host Disease

2008-05-27

2025-06-06

Treatments
EiFFEL

P3

Unknown status

Graft vs Host Disease

2022-12-01

20%

2024-06-04

Primary Endpoints|Treatments|Trial Status
2007-005009-24

P3

Completed

Graft vs Host Disease|Allogeneic Stem Cell Transplant

2015-02-16

2022-03-12

Treatments

Recent News Events

Date

Type

Title

06/20/2023

PubMed

 Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.

09/21/2021

PubMed

 Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease.

04/15/2021

News Article

 While ElsaLys continues to work on the filing of marketing approval in Europe and the U.S. for inolimomab, the company confirms the renew of its cohort ATU in France and compassionate use programs submissions in several other countries

03/05/2021

PubMed

 Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.

01/19/2021

News Article

 Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease

01/19/2021

News Article

 Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease

07/23/2020

News Article

 ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions